Blandt forsøgspersoner, som var naive over for 14 almindelige HPV- typer og som havde en negativ Pap- test ved dag 1, reducerede indgivelsen af Silgard incidensen af CIN 2/ 3 eller AIS forårsaget af vaccine - eller ikke- vaccine- HPV- typer med 42, 7% (95% CI:
Among subjects who were naïve to 14 common HPV types and had a negative Pap test at Day 1, administration of Silgard reduced the incidence of CIN 2/ 3 or AIS caused by vaccine- or non-vaccine HPV types by 42.7% (95% CI: